Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 23, 2023

Novel TIM-3 Antibody Sabatolimab Plus Decitabine or Azacitidine for High- or Very High–Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

American Journal of Hematology


Additional Info

American Journal of Hematology
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes
Am. J. Hematol 2023 Nov 22;[EPub Ahead of Print], AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, G Garcia-Manero, N Vey, M Wermke, JJWM Janssen, R Narayan, S Fleming, S Loo, N Tovar, M Kontro, OG Ottmann, P Naidu, H Sun, M Han, R White, N Zhang, A Mohammed, CA Sabatos-Peyton, DP Steensma, ML Rinne, UM Borate, AH Wei

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading